BioMarin Pharmaceutical Inc.

Last updated September 27, 2026
Favorite this organization

Organization details

Legal name
BioMarin Pharmaceutical Inc.
Ownership
Public
Status
Active
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Delaware
Headquarters city
Novato
Headquarters state / province
California
Headquarters country
United States
Fiscal year end
December
Ticker symbol
BMRN
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001048477
EIN
68-0397820

Board of directors

Follow this board

Chief executives

Alexander Hardy · Chief Executive Officer
Since December 2023

Director election results

Annual meeting of June 2, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

13 of this board's directors also sit on 37 other boards.

Network of BioMarin Pharmaceutical Inc.'s board connections Agios Pharmaceuticals Inc. Agios Pharmaceuticals... Alnylam Pharmaceuticals Inc. Alnylam Pharmaceutical... Ascendis Pharma A/S Ascendis Pharma A/S Century Therapeutics Inc. Century Therapeutics I... Charles River Laboratories International Inc. Charles River Laborato... Corvus Pharmaceuticals Inc. Corvus Pharmaceuticals... Embecta Corp. Embecta Corp. Enovis Corporation Enovis Corporation Geron Corporation Geron Corporation GoodRx Holdings Inc. GoodRx Holdings Inc. Guardant Health Inc. Guardant Health Inc. Henry Schein Inc. Henry Schein Inc. Immunome Inc. Immunome Inc. Incyte Corp. Incyte Corp. Insmed Incorporated Insmed Incorporated Iovance Biotherapeutics Inc. Iovance Biotherapeutic... Athena Countouriotis Athena Countouriotis Barbara W. Bodem Barbara W. Bodem David E. I. Pyott David E. I. Pyott Elizabeth M. Anderson Elizabeth M. Anderso... Ian T. Clark Ian T. Clark Jean Jacques Bienaime Jean Jacques Bienaim... Mark J. Enyedy Mark J. Enyedy Maykin Ho Maykin Ho Robert J. Hombach Robert J. Hombach Timothy P. Walbert Timothy P. Walbert BioMarin Pharmaceutical In...
Shared director Other board Same sector +21 more in the list below

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$0
0 purchases by 0 insiders
Sold, last 12 months
$4,318,240
5 sales by 3 insiders
Date Insider Transaction Shares Price Value
Sep 10, 2026 Robert M. Plenge Director Grant or award +6,140 — —
Sep 2, 2026 Davis George Eric Officer (EVP, Chief Legal Officer) Open-market sale −17,557 $66.28 $1,163,748
Jun 2, 2026 Athena Countouriotis Director Grant or award +7,490 — —
Jun 2, 2026 Timothy P. Walbert Director Grant or award +7,490 — —
Jun 2, 2026 Maykin Ho Director Grant or award +7,490 — —
Jun 2, 2026 Robert J. Hombach Director Grant or award +7,490 — —
Jun 2, 2026 Mark J. Enyedy Director Grant or award +7,490 — —
Jun 2, 2026 Willard H. Dere Director Grant or award +7,490 — —
Jun 2, 2026 Ian T. Clark Director Grant or award +7,490 — —
Jun 2, 2026 Barbara W. Bodem Director Grant or award +7,490 — —
Jun 2, 2026 Elizabeth M. Anderson Director Grant or award +7,490 — —
May 20, 2026 Hubbard Cristin Officer (EVP, Chief Commercial Officer) Shares withheld for tax −2,318 $50.20 $116,364
May 7, 2026 Friberg Gregory R Officer (EVP, Chief R&D Officer) Open-market sale −3,281 $53.85 $176,682
Mar 18, 2026 Davis George Eric Officer (EVP, Chief Legal Officer) Shares withheld for tax −1,273 $56.05 $71,352
Mar 17, 2026 Guyer Charles Greg Officer (EVP, Chief Technical Officer) Shares withheld for tax −1,693 $56.05 $94,893

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.